Melanocortin peptides, derived from POMC (proopiomelanocortin) are produced in the ARH (arcuate nucleus of the hypothalamus) neurons and the neurons in the commissural NTS (nucleus of the solitary tract) of the brainstem, in anterior and intermediate lobes of the pituitary, skin and a wide range of peripheral tissues, including reproductive organs. A hypothetical model for functional roles of melanocortin receptors in maintaining energy balance was proposed in 1997. Since this time, there has been an extraordinary amount of knowledge gained about POMC-derived peptides in relation to energy homoeostasis. Development of a Pomc-null mouse provided definitive proof that POMC-derived peptides are critical for the regulation of energy homoeostasis. The melanocortin system consists of endogenous agonists and antagonists, five melanocortin receptor subtypes and receptor accessory proteins.
INTRODUCTION
A hypothetical model for functional roles of MCRs (melanocortin receptors) in maintaining energy balance was proposed in 1997 [1] . This model comprised leptin, NPY (neuropeptide Y) and MCH (melanin-concentrating hormone) regulation of POMC (pro-opiomelanocortin)-derived peptide signalling in the hypothalamus, and MCR regulation of POMC peptide release from the pituitary, leptin release from adipose tissue, insulinsensitivity and thermogenesis in the periphery. Since this time, there has been an extraordinary amount of knowledge gained about POMC-derived peptides in relation to energy homoeostasis. Today, the melanocortin system is recognized as a critical player in body weight regulation and metabolism, at least for mammals [2] and fish [3] . Understanding the genotype and phenotype of the dominant agouti yellow obese mouse was fundamental to the development of hypotheses regarding roles for POMCderived peptides in obesity, and accelerated our knowledge of critical roles for the melanocortin system in energy homoeostasis [1] . The melanocortin system consists of endogenous agonists (POMC-derived peptides) and antagonists [agouti protein and AgRP (agouti-related peptide)], five MCR subtypes (MC1R-MC5R) and MRAPs (MCR accessory proteins). The present review is a discussion of the current understanding about roles and mechanism of action of POMC, MCRs and AgRP in obesity and Type 2 diabetes and how the central and/or peripheral melanocortin systems mediate nutrient, leptin, insulin, gut hormone and cytokine regulation of energy homoeostasis. Included in the present review are comparisons of how the 1997 hypothetical model for functional roles of MCRs in maintaining energy balance match up with our current knowledge in the field. Finally, I have included a discussion of recent developments in melanocortin signalling involving MRAPs, β-defensin 3 and MC4R auto-antibodies, areas of research which may be important in the future for progressing our understanding of how the melanocortin system regulates energy homoeostasis.
POMC-DERIVED PEPTIDES
Melanocortin peptides, derived from POMC (Figure 1 ), are produced in the ARH (arcuate nucleus of the hypothalamus) neurons and the neurons in the commissural NTS (nucleus of the solitary tract) of the brainstem, in anterior and intermediate Abbreviations used: ACTH, adrenocorticotropin; AgRP, agouti-related peptide; AMPK, AMP-activated protein kinase; ARH, arcuate nucleus of the hypothalamus; BAT, brown adipose tissue; BDNF, brain-derived growth factor; BMI, body mass index; CCK, cholecystokinin; CLIP, corticotropin-like intermediate lobe peptide; CPE, carboxypeptidase E; CREB, cAMP-response-element-binding protein; CRH, corticotropin-releasing hormone; CRTC2, CREB-regulated transcription co-activator 2; dpmARH, dorsomedial posterior arcuate nucleus; DVC, dorsal vagal complex; FGD, familial glucocorticoid deficiency; FOXO1, forkhead box O1; GABA, γ-aminobutyric acid; ICV, intracerebroventricular; IL, interleukin; K ATP , ATP-dependent K + ; LHA, lateral hypothalamic area; LIF, leukaemia inhibitory factor; LPH, lipotropin; MCH, melanin-concentrating hormone; MCR melanocortin receptor; MHb, medial habenula nucleus; MRAP, MCR accessory protein; MSH, melanocyte-stimulating hormone; mTOR, mammalian target of rapamycin; NDP-MSH, [Nle 4 ,DPhe 7 ]α-MSH; Nhlh2, nescient helix-loop-helix 2; NPY, neuropeptide Y; NTS, nucleus of the solitary tract; PC, prohormone-converting enzyme; PI3K, phosphoinositide 3-kinase; POMC, pro-opiomelanocortin; PRCP, prolylcarboxypeptidase; PRV, pseudorabies virus; PVH, paraventricular nucleus of the hypothalamus; RMR, resting metabolic rate; SCN, suprachiasmatic nucleus; SF-1, steroidogenic factor 1; Sim1, single-minded gene 1; SNP, single nucleotide polymorphism; TORC, target of rapamycin complex; TrkB, tropomyosin receptor kinase B; UCP, uncoupling protein; VGAT, vesicular GABA transporter; VMH, ventromedial nucleus of the hypothalamus; VMHd1, dorsomedial portion of the VMH; WAT, white adipose tissue. 1 email kmountjoy@auckland.ac.nz lobes of the pituitary, skin and a wide range of peripheral tissues, including reproductive organs [4] [5] [6] . The exact melanocortin peptides produced at each one of these POMC mRNA expression locations and the functions of each specific endogenous melanocortin peptide produced are largely unknown, although relatively more is known about the melanocortin peptides produced in the anterior pituitary and in the brain. In corticotropic cells of the anterior lobe of the pituitary, the major end product is the 39-amino-acid peptide ACTH (adrenocorticotropin), also known as corticotropin. In the melanotrophs of the intermediate lobe of the pituitary, ACTH 1−39 is the precursor for ACTH 1−13 -NH 2 
[or desacetyl-α-melanocyte-stimulating hormone (desacetyl-α-MSH)], N-terminally acetylated MSH (α-MSH), N,O-bisacetyl-Ser
1 -α-MSH (diacetyl-α-MSH) in which a second acetyl group appears on the third amino acid, Ser 1 , possibly resulting from a spontaneous N → O shift of the N-terminal acetyl group, and CLIP (corticotropin-like intermediate lobe peptide or ACTH 18−39 ) (Figure 2 ). In the brain, the major end-products of POMC processing are desacetyl-α-MSH and β-endorphin [7, 8] . There are lesser amounts of α-MSH, diacetyl-α-MSH, ACTH, CLIP, γ -LPH (γ -lipotropin), JP (joining peptide), γ 3-MSH and [Lys]-γ 1-MSH (γ -MSH). β-MSH is also produced in human brain, but not in rodent pituitary and brain [8] . γ -MSH is similarly found in human brains, but not mouse, rat and guinea-pig brains, as the dibasic residue pair for processing of γ 3-MSH to γ -MSH is lacking in these species [7] . There are discrete regional differences in POMC processing in the brain. Whereas desacetyl-α-MSH and non-acetylated β-endorphin predominate in the ARH, α-MSH and acetylated β-endorphin predominate in the NTS [7] .
Regulation of food intake following administration of melanocortin peptides in rodent brain was first demonstrated in the 1980s [9] and has been reproducibly shown by many investigators over the last decade [10] [11] [12] . Naturally occurring melanocortin peptides that have been confirmed to inhibit food intake when administered to the brain are ACTH 1−24 , α-MSH and β-MSH.
Melanocortin peptides administered in the periphery can also regulate food intake [13, 14] , but whether they do this through actions in the periphery or through acting directly in the brain is still unclear. Very little α-MSH [15] [16] [17] or its synthetic analogue, MT-II [18, 19] , crosses the blood-brain barrier from the periphery. Desacetyl-α-MSH injected intramuscularly was reported in 1989 to increase food intake in lean and obese viable dominant agouti mice [13] , but this does not appear to have been followed up since this time. In contrast, physiological doses of desacetyl-α-MSH injected into the brain were shown to have no effect on food intake [20] and this has been confirmed in recent years by several groups including my own [10, 21] . It was proposed in 1989 that a defect in N-terminal acetylation of desacetyl-α-MSH could contribute to the development of obesity [20] , and this remains a plausible hypothesis [1, 21] . Many years ago, desacetyl-α-MSH was found to be more much more abundant than α-MSH in the ARH [22] [23] [24] [25] [26] , but not in brainstem [27] , and more recently this finding has been confirmed for the ARH [28] . The fact that the acetylation reaction is dynamically regulated by leptin [28] and dopamine [29] [30] [31] [32] , hormones that also regulate energy homoeostasis [33, 34] , suggests that acetylation of desacetyl-α-MSH is an important control pathway for the melanocortin system in energy homoeostasis. The regulation of hypothalamic ACTH 1−13 -NH 2 acetylation by dopamine is, however, debatable [35] .
Three known endogenous melanocortin peptides in humans, ACTH 1−24 , α-MSH and β-MSH are recognized for decreasing food intake in rodents through direct actions in the brain when they are exogenously administered. Future studies will determine whether each one of these peptides is naturally involved in appetite control or whether appetite regulation is the specific function of only one endogenous melanocortin peptide. Recently, PRCP (prolylcarboxypeptidase)-initiated degradation and inactivation of extracellular α-MSH was found to be critical for maintaining wild-type mouse body weight [36] , suggesting that endogenous The 'soup' of melanocortin peptides produced at any one site and at any one time is determined by the level of expression and activity of the various processing enzymes. A, N-terminal acetylation; des-α-MSH, desacetyl-α-MSH; N-AT, N-terminal acetylation; PAM, peptidyl α-amidating mono-oxygenase.
α-MSH is at least one, if not the sole, melanocortin peptide regulating mouse body weight. PRCP cleaves the penultimate proline residue from ACTH 1−13 [36] and therefore will degrade both desacetyl-α-MSH and α-MSH (Figure 2 ). Although PRCP is expressed in the hypothalamus in neuronal populations that send efferents to areas where α-MSH is released from axon terminals and therefore likely to be an important component of melanocortin signalling in the brain, PRCP is not specific to ACTH 1−13 . PRCP also cleaves penultimate proline residues from other neuropeptides such as angiotensinogen II and prekallikrein, and inactivation of these peptides may influence the phenotype observed when there is increased or decreased activity of PRCP.
Of course it remains possible that melanocortin peptides, such as desacetyl-α-MSH and γ -MSH that do not inhibit appetite when exogenously administered at physiological doses into the brain, may act as antagonists of endogenous ACTH 1−24 and/or α-MSH induced inhibition of appetite. In our 1997 hypothetical model for functional roles of melanocortin peptides in energy homoeostasis [1] , we proposed that desacetyl-α-MSH in the hypothalamus increased food intake. To date, this has not proved to be the case. However, interpretation of functional roles for individual melanocortin peptides administered into the brain should be approached with caution. Melanocortin peptides exist as a 'soup' in the brain, and the ingredients of this 'soup' are constantly changing. There are likely to be significant functional interactions not only between melanocortin peptides, but also between melanocortin peptides and other neuropeptides. Indeed, these interactions are well established between melanocortin peptides and β-endorphin [37, 38] or between melanocortin peptides and MCH [39] . Interestingly, in contrast with α-MSH which inhibits food intake, ACTH 18−39 or ACTH 22−39 administration into brains of starving rats resulted in a long lasting increase in feeding [40] . It remains to be determined whether antagonism exists between the melanocortin peptides in the brain and whether this in turn affects the regulation of food intake. For example, does desacetyl-α-MSH, ACTH 18−39 or ACTH 22−39 antagonize α-MSH or ACTH 1−24 actions in the brain, actions that when unopposed would normally inhibit food intake and decrease body weight?
POMC GENE ASSOCIATION WITH OBESITY AND TYPE 2 DIABETES

Mouse
Development of a Pomc-null mouse provided definitive proof that POMC-derived peptides are critical for the regulation of energy homoeostasis [14] . Remarkably, Pomc-null mice exist with minimal adrenal gland tissue and undetectable glucocorticoids. Male and female Pomc-null heterozygous and homozygous mice develop obesity that is gene-dose-dependent (body weight homozygous > body weight heterozygous) and influenced by genetic background {C57BL/6 Pomc-null mouse obesity > 129
[A(w)/A(w)] Pomc-null mouse obesity} [14, 41, 42] . Despite their obesity, Pomc-null mice are not diabetic, but they do have a defect in glucagon regulation [43] . When challenged with hypoglycaemia, they are unable to mount a counterregulatory glucagon response, thus identifying a potential role for POMC-derived peptides in the regulation of glucagon [43] . Glucagon levels were raised when either corticosteroid or α-MSH was administered to Pomc-null mice. POMC-derived peptides therefore appear to have a critical role in the regulation of pancreatic α-cell production of glucagon, at least in the absence of corticosteroids.
A major difficulty associated with identifying functions for POMC-derived peptides using the Pomc-null mouse model, particularly specific melanocortin peptide functions, is (i) the loss of all POMC-derived peptides in this mouse, including β-endorphin, and (ii) the absence of correctly functioning adrenal tissue and adrenal-gland-derived hormones such as glucocorticoids. The phenotype of the Pomc-null mouse is therefore influenced by the loss of the 'soup' of POMC-derived peptides and the consequent loss of glucocorticoids. The fact that the obesity phenotype can be reversed by peripheral administration of MT-II, a synthetic α-MSH analogue [14] , identifies a missing melanocortin peptide responsible for the obese phenotype, at least in the absence of all other POMC-derived peptides and adrenal glands. Interestingly, central administration of α-MSH, β-MSH or γ -MSH reduced appetite in Pomc-null mice, but only α-MSH significantly reversed the obesity [42] .
To better identify functions for specific melanocortin peptides in the future, specific melanocortin-peptide-knockout mice will be needed. Such mice will therefore express all POMCderived peptides, except the specific peptide to be investigated, and, providing ACTH 1−24 or ACTH 1−39 is not the missing peptide, the animal should develop adrenal glands and produce glucocorticoids. Such models could then be used to test biological functions for a specific POMC-derived peptide in the brain or in the periphery. To this end, we recently developed an ACTH 1−13 -null knockin mouse model in which the cleavage site required to cut ACTH 1−17 out of ACTH 1−39 was mutated to destroy cleavage of ACTH to ACTH 1−13 , while maintaining a full-length functional ACTH peptide required for adrenal gland development ([43a] and K. G. Mountjoy and S. J. Rynbeck, unpublished work).
Human
The first rare human POMC-null mutation [44] was reported around the time of the development of the Pomc-null mouse. In contrast with mice, humans are unable to exist without adrenal glands and glucocorticoid hormones. Humans with a POMC-null mutation only survive when they are supplemented with glucocortioids from birth and they can exhibit red hair, hyperphagia and obesity [45] , a remarkably similar phenotype to that seen in Pomc-null mice, thus emphasizing the highly conserved role for the POMC gene in the regulation of energy homoeostasis. Point mutations that disrupt specific melanocortin peptides have also been reported in humans [45, 46] and these produce various phenotypes, depending on the location of the mutation. A point mutation in the cleavage site between β-MSH and β-endorphin in humans causes obesity [47] , and it has been suggested that β-MSH may be the important endogenous anorectic melanocortin agonist for MC4R in humans [48] .
Disease genetics
Processing enzymes that cleave POMC precursor protein and also those that remove C-terminal residues (Figures 2 and 3 ) Figure 3 Regulation of POMC processing in the hypothalamus PC1, PC2 and CPE enzymes regulate the processing of the 'soup' of melanocortin peptides in POMC neurons in the ARH. Nhlh2 is a transcription factor that regulates PC1 and PC2 [52] . ProSAAS is a neuroendocrine peptide precursor that potently inhibits PC1 in vitro, and CPE is important for generating the active forms of proSAAS [257] . Transgenic mice overexpressing proSAAS develop obesity. 7B2 peptide is a regulator/activator of PC2 and variation in its gene, SGNE1 (secretory granule neuroendocrine protein 1) may worsen glucose intolerance and insulin resistance, especially in the background of severe and early-onset human obesity [258] . MC3R is an autoreceptor for melanocortin peptide production [144] . N-AT, N-terminal acetylation.
are associated with obesity in rodents and humans [4] . PC (prohormone-converting enzyme) 1-mutant mice [49] and humans with mutations that partially eliminate functional PC1 [50] , develop obesity. PC1, however, is not specific for POMC cleavage and therefore this is not a good model for furthering our understanding of roles for POMC-derived peptides in obesity and Type 2 diabetes. Mice with a deletion of the hypothalamic basic helix-loop-helix transcription factor Nhlh2 (nescient helix-loophelix 2), on the other hand, may prove to be a useful model for understanding how POMC processing contributes to obesity. In mice, targeted deletion of the Nhlh2 gene results in adult onset obesity [51] .
Nhlh2 co-localizes with POMC in ARH neurons and Nhlh2 expression is significantly reduced in ARH neurons following 24 h of food deprivation or cold exposure [52] . Nhlh2 regulates transcription of PC1 and PC2 (Figure 3 ), possibly in conjunction with the leptin-stimulated transcription factor STAT3 (signal transducer and activator of transcription 3) [52] . In the future, it will be of interest to determine the influence of Nhlh2 gene deletion on the relative amounts of the various POMC-derived peptides. It is possible that it is the relative level of certain POMC-derived peptides rather than one specific peptide that ultimately regulates energy homoeostasis. Support for α-MSH as the POMC-derived peptide responsible for regulating food intake was provided when PRCP was discovered to inactivate α-MSH and Prcp-null mice had elevated hypothalamic levels of α-MSH and were leaner than wild-type control mice [36] (Figure 2) .
A spontaneous point mutation in the coding region of the mouse Cpe (carboxypeptidase E) gene resulted in the loss of CPE activity that correlated with the development of late-onset obesity [53] and this mouse had reduced levels of circulating ACTH and increased circulating POMC levels [54] . The Cpe gene encodes the major enzyme responsible for the C-terminal trimming of basic amino acids from POMC-derived peptides, and other neuropeptides, after the activation of PCs [55] . CPE is also a sorting receptor for the regulated POMC secretory pathway [54] .
MELANOCORTIN RECEPTORS ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES
Of the five MCR subtypes, MC4R is the one receptor that is critical for mammalian appetite and body weight regulation [56] , glucose homoeostasis [57] , hepatic lipid metabolism [58] and nutrient partitioning [58] . MC3R is also critical for body weight regulation, at least in mice. Physiological roles for all of the other MCR subtypes in energy homoeostasis are likely to exist, but are either not yet identified or not clearly defined.
Mouse MC4R
In the 1997 hypothetical model [1] , MC4R was hypothesized to be important for body weight regulation following mapping of Mc4r mRNA expression to the hypothalamus in rodent brain [59] and the discovery that agouti protein is an antagonist of melanocortin peptide activation of MC4R in the dominant agouti obese mouse [60] . Proof that MC4R is critical for body weight regulation was provided with the development of Mc4r-knockout mice [61, 62] and discoveries of point mutations in human MC4R associated with obesity [63, 64] . The phenotype of the Mc4r-knockout mouse indicated physiological roles for MC4R in regulation of appetite, body weight, linear growth, lean mass, glucose homoeostasis, insulin secretion and sensitivity, bone mineral content, and sympathetic nervous system-driven responses [57, 61, 65, 66] . Just as the phenotype of the Pomc-null mouse is strain-dependent, so too is the phenotype of the Mc4r-knockout mice. The severity of the phenotype was greater on the C57Bl/6J background compared with the SV129 mixed background [41, 67] .
Human MC4R
Phenotypes of humans with a defective MC4R revealed physiological roles for human MC4R in the regulation of appetite, body weight, height, bone mineral content and cardiovascular function, but not in glucose homoeostasis [63, 64, [68] [69] [70] [71] . Single nucleotide variations in just one allele of the human MC4R coding sequence that result in a defect in signal transduction through MC4R can cause obesity. These nucleotide variations occur throughout the entire human MC4R coding sequence and often result in intracellular retention of MC4R [68, 70, [72] [73] [74] . Interestingly, to date, only one variation in the human MC4R 5 -UTR (untranslated region) has been reported that could be associated with obesity [75, 76] . Valli-Jaakola et al. [76] discovered a 2 bp deletion (− 439delGC) that would destroy an Nhlh2-binding site and heterozygous − 439delGC carriers displayed an obese phenotype similar to that for defective coding region human MC4R mutations. Nhlh2 may therefore regulate the processing of POMC peptides and also regulate transcription of MC4R, but this has yet to be proven.
Defective human MC4Rs account for ∼ 1-6 % morbidly obese individuals across diverse ethnic groups [68, 77, 78] . The frequency of MC4R mutations varies between different ethnic populations being lower in some Mediterranean, German and Asian populations compared with the British population [77, [79] [80] [81] [82] [83] . Remarkably, the most common polymorphism in the human MC4R coding region, V103I, does not appear to have a major effect on MC4R biological activity in vitro, although it may subtly enhance antagonism and agonism [70, 80, [84] [85] [86] . The V103I polymorphism has been associated with protection from obesity in the general human population in a number of different ethnic groups [84, [87] [88] [89] . Although the mechanism whereby this polymorphism protects humans from obesity is unknown, its identification emphasizes an important role for MC4R in body weight regulation in the general human population. A borderline significant association of the MC4R V103I variant with a high carbohydrate intake frequency has been reported [87] . Interestingly, in the starved state, the MC4R V103I variant has also been reported to associate with high energy expenditure, high rates of glucose oxidation and lower levels of non-esterified 'free' fatty acids [90] , all of which might be expected if the diet is enriched with carbohydrate [91] . A second less-common variation in the human MC4R, I251L, is also associated with protection from obesity [92] and this is more striking than the V103I polymorphism. The MC4R Leu 251 allele is associated with decreasing the risk of obesity to nearly 50 % in obese/general and childhood/middle-aged adult populations of European descent [92] . Although the mechanism for the human MC4R I251L variant protection from obesity is unclear, stably expressing this MC4R variant in HEK (human embryonic kidney)-293 cells showed that it had increased basal activity compared with the MC4R I251L variant [84] . Increased MC4R basal activity is consistent with protection from obesity.
Mouse MC3R
Expression of Mc3r mRNA, like Mc4r mRNA, mapped to rat hypothalamus [93] indicating a potential physiological role for MC3R in energy homoeostasis. Development of the Mc3r-knockout mouse model provided proof that MC3R is important for maintenance of energy homoeostasis [94, 95] . The phenotype of the Mc3r-knockout mouse differed from that of the Mc4r-knockout mouse, thus identifying different and non-redundant mechanisms underlying MC4R-and MC3R-driven obesity. The obese phenotype of the Mc3r-knockout mouse appeared to be due to reduced feed efficiency and locomotor activity, altered energy partitioning and altered pattern of feeding. Development of the Mc3r/Mc4r-double knockout mouse provided further support for MC3R and MC4R complementary mechanisms driving obesity, since this mouse model exhibited greater obesity compared with either receptor-knockout mouse model alone [94] . Similar to Pomc-null and Mc4r-null mice, the phenotype of the Mc3r-null mouse is strain-dependent, and the severity of the phenotype was greater on the C57Bl/6J background compared with the SV129 mixed background [41, 67] .
Human MC3R
The importance of human MC3R in the regulation of human body weight is not clear, but it is clear that defects in the coding of human MC3R that may be associated with human obesity are much fewer than those in human MC4R [96, 97] . In humans, one heterozygous mutation has been found that completely eliminates a functional human MC3R and therefore it is unknown whether this receptor is critical for body weight regulation. The fact that human MC3R mutations that result in complete loss of MC3R function are absent, despite intense searches for these in obese cohorts, could imply that the human MC3R is critical for human survival. Two common SNPs (single nucleotide polymorphisms) in human MC3R, T6K and V81I, have been reported to be associated with childhood, but not adult, obesity [97] , and they are not associated with Type 2 diabetes [98] . There are conflicting data over whether either of these SNPs could impair signalling through MC3R expressed in heterologous cells. Lee et al. [97] reported that both SNPs impair MC3R signalling, whereas we and others [99] found no effect of these SNPs on MC3R signalling in vitro. Three novel heterozygous MC3R mutations (A293T, I335S and X361S) were found in a group of 290 obese Caucasians, but not in 215 normal weight individuals [96] . The mutations segregated with obesity in the members of the families studied. Only the I335S mutation impaired the in vitro function of MC3R; it had complete loss of coupling to the cAMP signalling pathway and it was not expressed at the cell surface. The MC3R I335S mutation may represent a dominantly inherited form of human obesity.
It remains possible that there are more numerous variations in the human MC3R gene that associate with obesity and/or Type 2 diabetes, but they lie outside the coding region, thus affecting expression of MC3R. The human MC3R gene has not been described, but it maps to human chromosome 20q13.2 [100] , a locus associated with BMI (body mass index) and starving insulin [98, 101] . Although MC3R alone may not be critical for human body weight regulation, it could be an important contributor to human Type 2 diabetes. A polymorphic marker (D20S32e) located between − 1933 and − 1892 of the human MC3R coding sequence associated with starving insulin and the insulin-resistance index HOMA-R (homoeostasis model assessment for insulinresistance) in a 60-member Maori pedigree, suggesting that the regulation of MC3R expression may contribute to Type 2 diabetes [98, 102] . Furthermore, a + 2138InsCAGACC polymorphism 3 of the human MC3R coding region associated with less abdominal subcutaneous fat in obese (BMI 30 kg/m 2 ), but not normal weight (BMI < 25 kg/m 2 ), individuals, implicating MC3R in the regulation and distribution of adiposity in humans [103] .
Mouse and human MC1R, MC2R and MC3R
Mouse genetic studies did not indicate critical roles for Mc1r, Mc2r or Mc5r genes in body weight regulation, since an obese phenotype was not observed for recessive mice, the equivalent of an Mc1r- [104] , Mc2r- [105, 106] or Mc5r-knockout mouse [107] . Similarly, obesity has not been reported in humans devoid of functional MC1R or MC2R [108, 109] . Similar to human MC3R, no complete loss-of-function human MC5R mutations have been reported. However, one genetic study has reported that a polymorphism, likely to be upstream of the human MC5R coding region, exhibits linkage or association with obesity phenotypes in a Québécois family study [110] . It remains possible that this polymorphism is in a gene other than MC5R.
MECHANISMS FOR MC4R IN THE REGULATION OF ENERGY HOMOEOSTASIS Food intake
PVH (paraventricular nucleus of the hypothalamus)
MC4R expression in the PVH, and possibly the amygdala, is critical for food intake regulation, since reintroduction of MC4R in the PVH and amygdala of the conditional Mc4r-mouse was sufficient to reverse the hyperphagia normally observed in this mouse model [111] . Further evidence supporting a critical role for MC4R expressed in the PVH for food intake regulation was provided when AAV (adeno-associated virus)-mediated knockdown of the Mc4r gene in the PVH promoted hyperphagia in adult rats fed on a high-fat diet [112] .
Signalling molecules that mediate the effect of MC4R on food intake are beginning to be identified ( Figure 4 ). MC4R is co-expressed with CRH (corticotropin-releasing hormone) on PVH neurons, and administration of CRH to rodent brain inhibits food intake [113] , a response also observed in the Mc4r-knockout mouse [114] . This suggested that CRH may act downstream of MC4R for food intake regulation. There is stronger evidence, however, supporting roles for Sim1 (singleminded gene 1), BDNF (brain-derived neuronal growth factor) and oxytocin as mediators of MC4R regulation of food intake. Sim1 is a transcription factor expressed in the PVH and amygdala of the brain [111] . Sim1-knockout mice are obese and resistant to melanocortin peptide inhibition of appetite [115] , whereas overexpression of Sim1 normalizes food intake in dominant agouti yellow obese mice [115] . Oxytocin is responsible for much of the hyperphagia of obese Sim1 +/− mice [116] and therefore oxytocin probably mediates at least some of the MC4R-driven inhibition of appetite. It is not known whether the oxytocin gene is a transcriptional target of Sim1, although the oxytocin promoter does not contain any consensus binding sites for Sim1 or its heterodimer partner, Arnt (aryl hydrocarbon receptor nuclear translocator), suggesting that Sim1 does not regulate the oxytocin gene directly. Activation of MC4R in PVH magnocellular neurons resulted in mobilization of intracellular calcium and induction of c-Fos, followed by dendritic oxytocin release in the supraoptic nucleus [117] . It is possible that activation of MC4R in the PVH to inhibit food intake involves this mobilization of intracellular calcium, induced c-Fos expression and oxytocin release ( Figure 4) .
Another potential mediator of MC4R signalling to reduce food intake is nesfatin-1. Central α-MSH administration to rat brain stimulated PVH nesfatin-1 mRNA, whereas central administration of SHU9119, an antagonist of MC4R, abolished nesfatin-1-induced feeding suppression [118] .
VMH (ventromedial nucleus of the hypothalamus)
BDNF and its receptor, TrkB (tropomyosin receptor kinase B), are associated with obesity in addition to neurodevelopment and synaptic plasticity. BDNF-deficient mice [119] and TrkBdeficient humans [120] are obese. The synthetic melanocortin peptide, MT-II, stimulated BDNF expression in the VMH of wild-type mice and BDNF suppressed feeding in obese Mc4r-knockout mice, all of which indicates a role for BDNF in the VMH mediating the MC4R effect on appetite initiated in the PVH. It is not known, however, whether MC4R signalling in the PVH is required to induce BDNF expression in the VMH.
Brainstem
Regions in the brain in which MCR blockade leads to alterations in energy balance include the hypothalamus and brainstem. Feeding and body weight are controlled by the dorsal motor nucleus of the vagus nerve (DMX) [121] , a region of high MC4R mRNA density in the brainstem that receives afferent projections from the gastrointestinal tract. The molecular mechanism whereby activation of brainstem MC4R results in decreased food intake is only starting to be unravelled. A critical role for MC4R in satiety suppression of food intake by CCK (cholecystokinin) mediated by melanocortin neurons in the brainstem was demonstrated using Mc4r-knockout mice [122] .
There is now strong evidence for a role of BDNF as a downstream mediator of MC4R signalling in the DVC (dorsal vagal complex) of the brainstem. Bariohay et al. [123] showed that delivery of the MC3R/MC4R agonist, MT-II, and the antagonist, SHU9119, into the fourth ventricle increased and decreased BDNF protein content respectively within the DVC. They also showed that the orexigenic effect of a selective MC4R antagonist, HS014, delivered into the fourth ventricle was blocked by coadministration of BDNF [123] .
It remains to be determined how this role of MC4R in satiety signalling in the brainstem integrates with MC4R-induced appetite suppression in the PVH. MC4R mRNA was found in the nodose ganglia (preganglionic motor fibres from the DVC leading to sympathetic activation), and electrophysiological and biochemical methods were used to provide evidence that MC4R signalling in the caudal brainstem leads to mainly presynaptic modulation of glutamatergic synaptic transmission [124] . Presynaptic MC4R may therefore modulate vagal glutamatergic inputs to the NTS in the brainstem.
Energy expenditure
Mc4r-null mice gain more weight compared with wild-type mice when given the same amount of food as a result of their lower energy expenditure [125] . ICV (intracerebroventricular) injection of a non-selective MCR agonist was only able to stimulate energy expenditure in animals with a functional MC4R, which supports a role for MC4R in the regulation of energy expenditure [126] . Humans with a defective functioning MC4R are obese, but do not always appear to have reduced energy expenditure. Farooqi et al. [63] reported that MC4R deficiency in humans had no effect on energy expenditure, whereas reduced energy expenditure was found in Pima Indians with genetic defects in MC4R [127] . Although the neuroanatomical sites critical for MC4R-mediated energy expenditure in mice have not yet been identified, it is known that MC4R regulation of energy expenditure is mediated through activation of the sympathetic nervous system involving sites in the hypothalamus and brainstem [128, 129] , and the MC4R-mediated increase in body temperature is dependent on the acute release of hypothalamic BDNF [130] . The neuronal endocrine secreted peptide precursor VGF may function in MC4R-regulated projections to liver, WAT, BAT and pancreas [137] .
Sympathetic nervous system
The discovery that MC4R mRNA is expressed in the IML (intermediolateral cell column) [131, 132] , which, in the rat, projects to postganglionic neurons innervating BAT (brown adipose tissue), first implicated the sympathetic nervous system in MC4R regulation of energy expenditure. BAT also receives inputs from other autonomic control regions expressing MC4R mRNA such as the ventromedial preoptic nucleus, PVH, LHA (lateral hypothalamic area) and rostral ventrolateral medulla [59, 132] . Rats injected centrally with MT-II, a potent synthetic melanocortin peptide analogue, exhibited a slight but significant exaggerated body fat loss compared with their pair fed counterparts, implicating both lipid mobilization and increased thermogenesis that occurs via the sympathetic nervous system outflow to WAT (white adipose tissue) and to BAT [128, 133, 134] . A transneuronal viral retrograde tract tracer, the PRV (pseudorabies virus), was used to map the regions in the brain where sympathetic outflow to WAT and BAT originate [135, 136] . The highest percentages of PRV-infected cells that co-express MC4R RNA were laterodorsal tegmental nucleus and the rostral raphe pallidus following PRV injection into BAT, and the PVH following PRV injection into WAT. Song et al. [136] were able to stimulate thermogenesis by injecting MT-II in the PVH of Siberian hamsters, suggesting that MC4R in the PVH regulates energy expenditure, at least in Siberian hamsters. In contrast, restoration of MC4R expression specifically in Sim1-expressing neurons in PVH and amygdala of the conditional Mc4r-knockout mouse identified these neuronal locations as critical for MC4R-mediated regulation of food intake, but not for energy expenditure [111] . The exact neuronal populations critical for MC4R-mediated effects on energy expenditure therefore remain to be determined and may be species-specific.
The neuronal endocrine secreted peptide precursor called VGF may function in melanocortin regulated sympathetic projections to WAT that control lipolysis, and melanocortin regulated sympathetic projections to pancreas and liver that control glucose homoeostasis ( Figure 5) . A role for the Vgf gene in energy homoeostasis was identified when Vgf −/− mice were found to have a lean and hypermetabolic phenotype [137] . Ablation of the Vgf gene in A y /a mice completely suppressed the obese agouti phenotype, suggesting that VGF is required for the development of agouti-induced maturity onset obesity [138] . VGF might therefore function in pathways downstream of MC4R that project via the autonomic nervous system to peripheral metabolic tissues ( Figure 5 ). Mice in the fed state showed co-localization of Vgf mRNA with α-MSH in ARH nuclei, and, during the starved state, VGF co-localized to a greater extent with ARC NPY neurons than with ARH POMC neurons [137] . A large number of AgRPcontaining ARH neurons co-express VGF and project to the PVH, where their processes terminate on thyrotropin-releasing hormone neurons [139] and on neurons in the dorsal and ventral parvocellular subdivisions, areas rich in Mc4r mRNA, that project to parasympathetic and sympathetic centres in the brainstem and spinal cord [140] . VGF is a polypeptide precursor encoding different physiologically active neuropeptides and its expression is limited to neurons within the central and peripheral nervous system and various endocrine cells [137] . The VGF peptides generated by PC1/3 and PC2 endoproteolytic cleavage, are stored in dense-core granules and then secreted through a regulated pathway [137] . The VGF C-terminal peptide TLQP-21 appears to upset energy balance in mice through centrally stimulating the autonomic nervous system possibly via central prostaglandin production and adipose tissue catabolism. It is currently unknown how VGF-derived peptides engage with the melanocortin system to upset energy balance.
MECHANISMS FOR MC3R IN THE REGULATION OF ENERGY HOMOEOSTASIS
Much less is known about the roles in energy homoeostasis for MC3R than for MC4R. Mc3r −/− mice exhibit a milder obese and insulin-resistant phenotype compared with Mc4r −/− mice [141] . Studies on the Mc3r-null mouse showed that MC3R probably plays a role in regulating feed efficiency, energy partitioning, locomotor activity [94, 95] and substrate metabolism during feed restriction [142] . Mc3r-null mice showed signs of failure to regulate fatty acid and carbohydrate metabolism during periods of intermittent nutrient availability. The molecular mechanisms behind these roles for MC3R (Table 1) are unknown, but the expression of MC3R in the hypothalamus [93] , gut and pancreas [143] has led to hypotheses for how MC3R may regulate energy homoeostasis.
Auto-inhibitory role
A role for MC3R in the regulation of POMC expression and/or processing was hypothesized on the basis of the expression of MC3R in POMC-expressing neurons in the ARH. Electrophysiological studies on neurons expressing green fluorescent protein under the control of the POMC promoter indeed showed that melanocortin peptides have an auto-inhibitory effect on POMC neurons [144] . Hence MC3R may play a role in energy homoeostasis through the regulation of POMC-derived peptides.
Entrainment of food availability
A hypothetical mechanism for MC3R regulation of energy homoeostasis is that this receptor links energy balance neural systems with those systems affecting entrainment to food availability [142] . The discovery that MC3R is critical for entrainment of anticipatory behaviour to feeding time was made because Mc3r-null mice exhibited abnormal daily patterns of feeding behaviour [145] . Maintaining circadian rhythms in energy consumption and expenditure is dependent on synchronization of oscillating clock genes in the forebrain [146, 147] , and MC3R deficiency results in impaired synchronization of clock genes [142] . Although the master pacemaker clock for light entrainable oscillation is located in the SCN (suprachiasmatic nucleus), the location of the food entrainable oscillator is uncertain. The VMHdl (dorsomedial portion of the VMH) shares strong connections with regions involved in appetite regulation, such as paraventricular and dorsomedial hypothalamic nuclei [148] , and may be involved in maintaining entrainment to feeding time. There is dense expression of MC3R in this area [93] . An even denser area for MC3R mRNA expression is the MHb (medial habenula nucleus) where a role for MC3R is unknown. Interestingly, the MHb is an additional site for synthesis of melatonin other than the pineal gland [149] and this raises the possibility that MC3R in the MHb may be involved in circadian rhythms, and even possibly entrainment of anticipatory behaviour to feeding.
Photoperiod
Recently, photoperiod changes were found to regulate MC3R mRNA expression in the dpmARH (dorsomedial posterior arcuate nucleus) of the Siberian hamster [150] . Vgf is another gene where expression in the dpmARH dramatically changes with photoperiod in the Siberian hamster and MC3R was found to coexpress with VGF in a small subpopulation of dpmARH neurons [150] . It is possible that VGF functions downstream of MC3R to regulate photoperiod-driven energy homoeostasis adaptations since VGF expression is regulated by a cAMP-dependent pathway [150] .
Food intake
Although there is ample data to indicate that it is hypothalamic MC4R and not MC3R that directly regulates food intake [2, 151] 
Insulin production
A significant increase in starving blood glucose levels was reported for older (>10 months) Mc3r-knockout mice [153] and for Mc3r-knockout mice fed a high-fat diet compared with wild-type mice [154] . This suggested that MC3R is required for β-cell insulin production to compensate for insulin resistance. If activation of MC3R in the periphery results in increased β-cell insulin production and decreased blood glucose, this may in turn stimulate appetite. A role for MC3R in the regulation of insulin production was supported by the discovery that BIM-22511, a non-selective melanocortin agonist, failed to reduce starving insulin in Mc3r-knockout mice, but did significantly reduce starving insulin in Mc4r-knockout mice [153] .
Anti-inflammatory role
MC3R may be one of the major MCRs responsible for the antiinflammatory properties of melanocortin peptides and, perhaps through this role, it may also influence energy homoeostasis. Obesity is associated with a chronic low-grade inflammatory state arising from an imbalance between pro-inflammatory and antiinflammatory cytokines produced by both adipocytes and macrophages infiltrating adipose tissue, liver and muscles ( [155] , but see [155a] ). MC3R mRNA is expressed in inflamed mesenteric tissue and Mc3r-null mice exhibit an exacerbated inflammatory reaction of the microvasculature [156] , indicating a critical role for this receptor in controlling the vascular reactivity of the mesenteric microcirculation. Tissue-resident macrophages express MC3R, and it is thought that its activation would downregulate macrophage activation, leading to inhibition of the production of pro-inflammatory mediators and induction of proresolving and tissue-protective proteins [156] .
MECHANISMS FOR AgRP IN THE REGULATION OF ENERGY HOMOEOSTASIS
AgRP, the endogenous antagonist of both MC3R and MC4R, co-localizes with NPY-expressing ARH neurons [157] . Administration of AgRP or overexpression of AgRP in rat brain promotes weight gain by increasing food intake and reducing energy expenditure ( [158, 159] , but see [159a] , [160] ) and food intake can remain stimulated for up to 7 days [161] . It has been proposed that physiological modulation of MCR signalling may be accomplished mainly by alteration in the levels of AgRP rather than melanocortin peptides: starvation and leptin deficiency cause a predominant rise in hypothalamic levels of AGRP mRNA rather than a decrease in POMC mRNA levels [162] , and AgRP can act as an inverse agonist on MC4R [163, 164] and MC3R [163] . Yet AgRP does not always act as an antagonist of melanocortin peptide signalling; in some circumstances, AgRP acts as an inverse agonist [163, 164] and even as an agonist [165] . AgRP may be able to activate these MCRs independently of melanocortin peptides. Similar to MC3R and the MC4R agonist MT-II, AgRP evoked consistent inhibitory effects on VMH glutamatergic neurons [165] . Furthermore, the AgRP effect was additive with MT-II. This AgRP effect appeared to be independent of the actions of melanocortin peptides on G s -coupled MCRs, but instead to be mediated by G i /G o G-proteins. The VMH operates to reduce food intake, and, because VMH neurons project to the POMC neurons, it was proposed that AgRP-mediated inhibition of excitatory neurons in the VMH may secondarily serve to reduce excitation of the POMC cells and thereby further reduce the anorexigenic tone during times of lowered energy stores [165] .
AgRP termini are widely distributed in the brain, including the PVH, ARH, DMH (dorsomedial nucleus of the hypothalamus) and LHA nuclei structures [162] . MC3R is expressed in approx. 44 % of AgRP and approx. 31 % of POMC ARH neurons, but neither AgRP nor POMC neurons co-express MC4R mRNA [162] . This finding led to the proposal that MC3R may mediate a negative autoregulation of POMC-mediated signals, because POMC-induced activation of AgRP neurons via MC3R would terminate the postsynaptic effects of POMC [162] . The longlasting effect of AgRP on food intake does not appear to be via MC4R expressed in the PVH, but instead it may be mediated by hyperactive orexin-A neurons in the LHA and the CART (cocaineand amphetamine-regulated transcript) neurons in the ARH [161] .
LEPTIN, INSULIN, NUTRIENT, GUT HORMONE AND CYTOKINE REGULATION OF ENERGY HOMOEOSTASIS MEDIATED BY THE MELANOCORTIN SYSTEM
Specific hormones, nutrients and cytokines regulate the central melanocortin system (Figure 6 ).
Leptin and insulin
Leptin sensing in the central melanocortin system is necessary for normal energy homoeostasis [166, 167] . The two key populations of neurons in the ARH are the POMC-and AgRP-expressing neurons, both of which express the long form of the leptin receptor. When circulating leptin levels are high, leptin activates its receptors on POMC neurons. These POMC neurons then release melanocortin peptides such as α-MSH that in turn inhibit food intake, except when an individual is obese, in which case the individual is leptin-resistant [168] . Furthermore, when circulating leptin levels are high, leptin activates its receptors on AgRP neurons in the ARH to inhibit the release of AgRP, except in leptinresistant obese individuals. Leptin also reduces food intake via a mechanism that involves increased sensitivity to satiety signals [169, 170] . These effects of leptin on satiety probably involve POMC-responsive neurons in the NTS [171] . In contrast with the ARH POMC neurons, the NTS POMC neurons do not appear to be involved with leptin signalling in response to changes in energy status [172] .
Although leptin signalling through the central melanocortin system is required for leptin to regulate energy homoeostasis, this is not the only way leptin regulates appetite and body weight. Balthasar et al. [173] depleted leptin receptors specifically from POMC neurons and discovered that this caused only a mild obese phenotype in mice, compared with the obesity observed when leptin receptors were specifically deleted from the SF-1 (steroidogenic factor 1)-expressing VMH neurons that do not express POMC [174] . The combined deletion of leptin receptors in both ARH POMC and SF-1 VMH neurons resulted in greater obesity than deletion in either neuronal population alone, indicative of additive roles for leptin receptor signalling in body weight regulation [174] . Similarly, ablation of leptin receptors in ARH POMC and ARH AgRP neurons resulted in additive effects on obesity [175] . Hence leptin regulates body weight by directly signalling several different brain nuclei populations, each one of which makes a small contribution. Further support for leptin signalling in brain nuclei to reduce body weight in addition to its signalling in the ARH POMC neurons was provided when restoration of a functional leptin receptor specifically in POMC neurons in leptin-receptor-deficient Lepr db/db mice only slightly decreased mouse body weight [176] . Remarkably, this restoration of a functional leptin receptor specifically in POMC neurons in leptin-receptor-deficient Lepr db/db mice led to normalization of blood glucose levels and increased locomotor activity, despite profound obesity [176] . The melanocortin system therefore appears to play a critical role mediating leptin regulation of glucose homoeostasis. Similar to the leptin adiposity signal, pancreatic β-cellderived insulin circulates at levels proportional to adiposity and signals ARH POMC and AgRP neurons to regulate energy homoeostasis [177] and satiety [178] . Lin et al. [179] recently showed divergent effects of insulin signalling in the hypothalamus on energy expenditure and glucose production. These authors restored insulin receptors in either POMC or AgRP neurons in mice deficient in hypothalamic insulin receptors and found that insulin signalling in AgRP neurons decreased hepatic glucose production, whereas insulin signalling in POMC neurons promoted hepatic glucose production and activated melanocortinmediated increased energy expenditure.
Class 1A PI3K (phosphatidoinositide 3-kinase) signalling mediates leptin and insulin action in ARH POMC and AgRP neurons [180] . PI3K consists of an 85 kDa (p85) regulatory subunit which binds insulin receptor substrate and a 110 kDa (p110α or p100β) catalytic subunit that phosphorylates PtdIns(4,5)P 2 to PtdIns(3,4,5)P 3 , activating downstream molecules such as Akt and the forkhead box transcription factor FOXO1 (forkhead box O1). PI3K-mediated phosphorylation and subsequent nuclear exclusion of FOXO1 resulted in increased Pomc mRNA expression [181, 182] . FOXO1 not only negatively regulates Pomc transcription, but also inhibits Cpe gene expression, resulting in impaired POMC processing [183] . In mice, FOXO1 ablation in POMC neurons increased CPE expression, resulting in selective increases in α-MSH and β-endorphin, the products of CPE-dependent POMC processing. Approximately half of POMC neurons express p100α or p110β [180] . Studies on genetically modified mice in which p85, p110α or p110β were individually deleted from ARH POMC neurons collectively demonstrated that increased PI3K activity in POMC neurons improved insulin sensitivity, whereas decreased PI3K signalling in POMC neurons impaired glucose regulation and led to weight gain [184] . In ARH POMC and AgRP neurons, the p110β isoform appears to be the dominant catalytic subunit mediating insulin and leptin effects on energy homoeostasis [180] . Inactivating p110α in POMC or AgRP neurons did not affect leptin's responses [180] . Interestingly, the acute effects of insulin and leptin on POMC and AgRP neurons differ; insulin activates PI3K signalling, and leptin has the opposite effect [185, 186] .
Nutrients
Nutrient signalling is integrated with regulation of whole-body energy homoeostasis in the hypothalamus [187] (Figure 6 ). Subpopulations of hypothalamic neurons are sensitive to glucose, fatty acids and amino acids [188] . A subpopulation of POMC neurons (∼ 50 %) in the ARH of the hypothalamus is excited by glucose [189] . A role for glucose sensing by POMC neurons in the overall physiological control of blood glucose was demonstrated when glucose sensing via POMC neurons was disrupted by transgenic POMC neuron-specific expression of a mutant Kir6.2 K + channel subunit that prevented ATP-mediated closure of K ATP (ATP-dependent K + ) channels [190] . Glucose was found to stimulate α-MSH secretion from hypothalamic brain slices from wild-type mice in a dose-dependent manner, but not from POMCmut-Kir6.2 mouse hypothalamic slices [190] . Furthermore, glucose sensing was found to be defective in POMC neurons of wild-type mice fed a high-fat diet for 20 weeks and increased UCP (uncoupling protein) 2 activity was causally linked to this loss of glucose sensing [190] . Neuronal metabolism of glucose generates ATP that binds to and closes the K ATP channels on POMC neurons. This leads to reduced K + outflow, depolarization of the POMC neuron membrane, increased electrical activity and stimulation of α-MSH release [187] . Although disruption of POMC-specific K ATP channels in mice impaired glucose tolerance, it did not change body weight [190] .
AMPK (AMP-activated protein kinase), mTOR (mammalian target of rapamycin) and CREB (cAMP-response-elementbinding protein) co-activator CRTC2 (CREB-regulated transcription co-activator 2) are sensors for glucose and its metabolism in the hypothalamus [191, 192] . AMPK senses the intracellular AMP/ATP ratio that is increased when intracellular energy supply is low. AMPK is essential for glucose sensing in POMC and AgRP neurons [185] . Genetically modified mice with AMPK deleted from POMC neurons developed obesity caused by decreased energy expenditure, but not diabetes. TORC (target of rapamycin complex) 1 and CRTC2 are downstream neuronal AMPK targets. mTOR, a serine/threonine kinase, functions with a multiprotein TOR signalling complex of which there are two types, TORC1 and TORC2. TORC1 activity is particularly pronounced in AgRP neurons where its expression is stimulated by feeding [191] . Activated TORC1 would phosphorylate proteins critical for regulating energy homoeostasis. Leptin-and insulin-regulated PI3K and AMPK signalling also converge on TORC1 signalling in the hypothalamus [191] .
The amino acid leucine also signals the body's energy supplies to the hypothalamus. Leucine enters the brain from blood more rapidly than other amino acids [193] and its metabolism is sensed by AMPK. Neuronal leucine amino acid sensing, like glucose sensing, involves the melanocortin system. Leucine sensing involves ARH POMC neurons, PVH oxytocin neurons and neurons in brainstem NTS to reduce appetite [194] .
Gut hormones
Brainstem POMC and MC4R appear to directly enhance some satiation signals arising from the gastrointestinal tract via vagal afferent fibres [124] in addition to mediating leptin-and insulinenhancing satiety effects. The satiety hormone CCK, released postprandially from the small intestine, reduces food intake through binding to CCK1 receptors on the vagal nerve. This is followed by activation of POMC neurons in the NTS [122, 195] and subsequent activation of MC4R in the brainstem to reduce meal size without affecting meal frequency [196] . Activation of the melanocortin system therefore decreases meal size through increasing the brain's responsiveness to satiety signals such as CCK.
The mechanism of action for the hunger hormone ghrelin produced in the stomach also involves the melanocortin system. Ghrelin is a peptide hormone released into the circulation from the stomach during starving. Ghrelin travels to the hypothalamus where it binds its receptor, GHS-R (growth hormone secretagogue receptor), to signal increased appetite. In 2008, an elegant study by Tong et al. [197] demonstrated that GABA (γ -aminobutyric acid) release from AgRP expressing neurons is critical to restrain energy expenditure and critical for ghrelin-stimulated food intake, effects resulting from GABAergic-mediated inhibition of POMC neurons. Mice generated with an AgRP-neuron-specific deletion of VGAT (vesicular GABA transporter) were found to be lean, resistant to obesity and to have attenuated hyperphagic response to ghrelin [198] . Recording of inhibitory postsynaptic potentials in POMC neurons from control and AgRP neuron Vgat-deleted mice indicated that ghrelin-stimulated GABAergic input to POMC neurons is mediated by AgRP neurons [197] .
Enterostatin is the N-terminal pentapeptide proteolytically cleaved from pancreatic procolipase and is released in the small intestine after ingestion of dietary fat [199] . Enterostatin, administered centrally or peripherally, induces satiation in rats and specifically suppresses intake of a high-fat diet. Afferent hepatic vagal nerve activity is required for the feeding response to peripheral enterostatin, resulting in c-Fos expression in the NTS of the brainstem [200] . Injection of enterostatin into the LHA significantly increased extracellular serotonin (5-hydroxytryptamine) levels [201] , whereas enterostatin injected into the amygdala selectively reduced dietary fat intake through a MC4R signalling pathway [199] . Enterostatin is present in the hypothalamus, amygdala and cortex of the brain in addition to its release into the small intestine, and it probably reduces highfat feeding through increasing brain serotonin and subsequent activation of the melanocortin system to inhibit food intake.
Cytokines
Cytokine stimulation of POMC plays an important role not only in weight loss associated with chronic illness [202] , but also in energy homoeostasis [203, 204] . Cytokines constitutively expressed in the hypothalamus and in the adrenal cortex are involved in regulating development of the HPA (hypothalamicpituitary-adrenal axis), stress and appetite [205] [206] [207] . They do this largely by regulating POMC and AgRP gene expression and secretion of POMC-derived peptides. The pro-inflammatory cytokine LIF (leukaemia inhibitory factor) is highly induced in the hypothalamus and pituitary in response to relatively weak inflammation and, along with CRH, enhances POMC expression and ACTH secretion in response to emotional and inflammatory stress [208] . Central LIF gene therapy reduces appetite, probably through enhanced hypothalamic POMC-derived peptide secretion [209] . IL (interleukin)-18 is another pro-inflammatory cytokine that has a role in modulating immune function during stress [210, 211] and controls energy homoeostasis by suppressing appetite and feed efficiency [212] . IL-18 is expressed in endocrine tissues, including the adrenal and pituitary glands as well as in the hypothalamus, in addition to its expression in immune cells. Acute stress or ACTH stimulates IL-18 production in the adrenal cortex, but not in immune cells. It is possible that this ACTH-induced adrenal-gland-derived IL-18 circulates to the hypothalamus to suppress appetite through regulation of hypothalamic POMC gene expression, similar to LIF-mediated suppression of appetite [213] . Hypothalamic resistance to IL-18 may develop and this would explain the elevated IL-18 circulating levels measured in the obese [212] .
CENTRAL MELANOCORTIN SYSTEM REGULATES PERIPHERAL NUTRIENT PARTITIONING, LIPID METABOLISM AND GLUCOSE HOMOEOSTASIS
Nutrient partitioning
In 1997, we hypothesized that the central melanocortin system regulated the sympathetic nervous system and increased or decreased thermogenesis [1] . Today we know that the central melanocortin system controls peripheral nutrient partitioning by promoting fat storage via direct actions on liver, muscle and fat cell metabolism, all of which are mediated by the sympathetic nervous system and MC4R [58] (Figure 5 ). These effects, which precede changes in adiposity, determine the balance among cellular glucose uptake, triacylglycerol synthesis, lipid deposition and lipolysis, and are independent of food intake [58] . Blockade of central MC4R signalling promoted insulin resistance in skeletal muscle and BAT, but not in WAT where glucose uptake was enhanced and lipogenesis was stimulated. The central melanocortin system was shown to undergo very rapid changes shortly before expected meal times, indicative of a role regulating chronic energy balance [214] . Tschop et al. [215] therefore proposed that the central melanocortin system prepares glucose and lipid metabolism pathways in peripheral organs for more efficient storage of incoming nutrients. These actions of the melanocortin system can be pharmacologically manipulated, and future understanding of these signalling pathways could eventually lead to novel treatments for Type 2 diabetes.
Hepatic lipid metabolism
Central melanocortin signalling via the vagus nerve appears to be crucial for the control of hepatic lipid metabolism [216] . Increased accumulation of hepatic triacylglycerols and their rapid transport to WAT resulted when the central melanocortin system was blocked [58] . ICV injection over 3 days of SHU9119, the MC3R/MC4R antagonist, increased hepatic triacylglycerol content and mRNA levels of the lipogenic genes SREBP-1C (sterol-regulatory-element-binding protein 1C) and PPARγ 2 (peroxisome-proliferator-activated receptor γ 2), without altering expression of hepatic genes involved in the biosynthesis of triacylglycerols or lipid droplet formation. This suggests that reduced central melanocortin signalling increases hepatic lipid deposition via increased uptake of lipoprotein particles, increased hepatic lipogenic gene expression and reduced hepatic fatty acid oxidation [217] .
Glucose homoeostasis
Serotonin 2C receptor (5-HT 2c R) agonists significantly improve glucose tolerance and hyperinsulinaemia in murine models of obesity and Type 2 diabetes via a mechanism involving MC4R stimulation of the sympathetic nervous system [57] . Serotonin agonists such as D-phenfluramine were used therapeutically in the past for their anorectic properties, but were withdrawn from the market in 1997 because of deaths from cardiac failure [218] . Interestingly, serotonin-agonist-induced improvements in glucose homoeostasis occurred at concentrations that had no effect on body weight and therefore these lower doses could be safe for treating Type 2 diabetes. Serotonin, via action at the serotonin 1B receptors (5-HT 1B Rs), modulated the endogenous release of α-MSH and AgRP to induce hypophagia via actions involving the central MC4R [219] .
PERIPHERAL EFFECTS OF THE MELANOCORTIN SYSTEM ON ENERGY HOMOEOSTASIS
The peripheral effects of melanocortin peptides on energy homoeostasis have not been as well studied as the central effects even though MC4R mRNA is expressed in the periphery [131, 220, 221] . Despite Nogueiras et al. [58] finding no detectable changes in rat body weight, body fat, thermogenesis or lipid metabolism following 7 days of peripheral infusion of SHU9119 or MT-II, melanocortin peptides have been shown to have direct effects on numerous peripheral organs, including adipose tissue, skeletal muscle, adrenal cortex and pancreas, and MCR subtypes are expressed on these peripheral tissues: MC1R, MC2R, MC4R and MC5R in adipose tissue [110, 222] ; MC2R, MC3R, MC4R and MC5R in adrenal cortex [223, 224] ; MC1R, MC3R, MC4R and MC5R in skeletal muscle [225] ; and MC3R in pancreas [143] .
Food intake
Stimulation of MC3R by peripheral administration of a moderately selective MC3R agonist [D-Trp 8 ]γ -MSH increased food intake and this was thought to be through MC3R-mediated stimulation of neurons co-expressing NPY and AgRP [152] . Since MC3R is expressed in circumventricular organs, peripherally administered [D-Trp 8 ]γ -MSH could potentially bind MC3R through its leakage across the blood-brain barrier. Recent data indicated that peripheral administration of a moderately selective MC3R antagonist, D-PG946 [226] , did not affect food intake, but peripheral administration of PG932, a non-selective antagonist of MC3R and MC4R and a derivative of SHU9119, was highly effective at stimulating appetite. This effect of PG932 required a functional MC4R, although it is unknown whether this is MC4R expressed in the brain or in the periphery, or both sites of expression. In contrast with PG932, SHU9119 only increased food intake when administered by ICV injection, but not peripherally, and yet it antagonized NDP-MSH ([Nle 4 ,D-Phe 7 ]α-MSH) reduction in serum insulin levels when given peripherally [227] . SHU9119 is an antagonist of MC3R and MC4R, but an agonist of MC1R and MC5R, and therefore its peripheral and central effects could be mediated through different MCR subtypes. The potent non-selective melanocortin peptide agonist MT-II, administered either centrally or peripherally, inhibited appetite and stimulated c-Fos expression in the brain, but the pattern of c-Fos induction differed between central and peripheral administration of MT-II [19] . In vitro autoradiographic studies on rats given 125 I-labelled MT-II intravenously demonstrated that MT-II had very limited brain penetrance capability, but it accumulated in a group of circumventricular organs, including the subfornical organ, median eminence, area postrema and choroid plexus [19] . Could central MT-II therefore affect appetite by acting directly on MC4R in the PVH and could peripheral MT-II indirectly inhibit appetite through influencing POMC peptides produced in the ARH or brainstem? MT-II is an agonist for MC1R, MC3R, MC4R and MC5R, and it could therefore act through one or more MCR subtype, either centrally or peripherally to regulate appetite and brain c-Fos expression.
Insulin secretion and activity
Peripheral and central injections of MC4R agonists have been shown to reduce serum insulin levels through melanocortin regulation of sympathetic outflow to the pancreas [228] . The regulation of glucose metabolism is acute and is independent of effects on food intake and weight loss [229] . Recently, peripheral administration of a non-selective melanocortin agonist BIM-22511 was found to significantly reduce starving insulin and improve insulin sensitivity in Mc4r-knockout mice without reducing food intake, body weight or hepatosteatosis [153] , indicating that peripherally administered melanocortins do not require MC4R for improvements in hyperinsulinaemia. α-MSHtreated skeletal muscle stimulated fatty acid oxidation through activation of the protein kinase A/AMPK signal transduction pathway and this probably involved MC5R [225] . The amount of triacylglycerols in skeletal muscle is closely associated with insulin resistance [230] and therefore this peripheral effect of α-MSH may be important for regulating energy partitioning and whole-body energy homoeostasis.
Leptin production
In our 1997 hypothetical model for functional roles of MCRs in maintaining energy balance, we proposed that α-MSH and ACTH 1−39 inhibited adipose tissue leptin production and leptin reciprocally stimulated α-MSH secretion [1] . Today there is convincing evidence for a peripheral action of melanocortins in the regulation of leptin expression in adipocytes and evidence supporting a regulatory loop that depends on the underlying state of energy homoeostasis [222, 231] . Melanocortin peptide regulation of leptin appears to be species-dependent. α-MSH decreased leptin mRNA in cultured rat differentiated adipocytes, and this effect was antagonized by AgRP [222] . Interestingly, AgRP alone was able to decrease leptin production by 40 % in cultured rat adipocytes in the absence of serum [232] . MC4R and MC5R are expressed in rat adipocytes [222] and probably mediate melanocortin peptide regulation of leptin production in rats. However, MC2R and MC5R are the most abundant MCRs expressed in differentiated 3T3-L1 adipocytes and mouse adipose tissue and are believed to be the receptors mediating ACTH and α-MSH effects on mouse fat cells [233, 234] . MC1R and MC4R have been detected in human adipose tissue [235] and are likely to be the main MCRs regulating leptin production and adipocyte lipolysis in humans.
Lipolysis
Melanocortin peptides, ACTH, α-MSH, desacetyl-α-MSH and β-LPH (β-lipotropin) have been known for some time to stimulate lipolysis and the potency of these peptides for lipolysis appears to be both species-and tissue-dependent. Desacetyl-α-MSH had greater lipolytic activity than that of α-MSH on cultured rabbit adipocytes [236] , whereas desacetyl-α-MSH, but not ACTH or α-MSH, induced lipolysis in rainbow trout liver, the main storage site for lipids in teleosts, both in vivo and in vitro [237] . ACTH stimulated lipolysis in rat visceral, but not in subcutaneous, adipose tissue [238] .
Pre-adipocyte proliferation and adipogenesis
Melanocortin peptides influence pre-adipocyte proliferation and adipogenesis in addition to lipolysis, and MC1R appears to be involved. α-MSH, but not ACTH, inhibited both mouse and human pre-adipocyte proliferation [239] , and agouti protein, but not AgRP, blocked the α-MSH inhibition of proliferation, indicative of an MC1R-mediated anti-proliferative effect [239] . Furthermore, agouti mRNA, which is expressed in human, but not rodent, adipose tissue, was increased in subcutaneous fat from individuals with Type 2 diabetes. In human adipose cells, glucocorticoids, but not insulin, up-regulated agouti mRNA expression [239, 240] . This suggests that agouti protein is a paracrine factor in human adipose tissue where it may promote both proliferation and adipogenesis.
Insulin sensitivity
ACTH has been shown to directly affect insulin sensitivity and pro-inflammatory adipokine expression in cultured mouse white adipocytes [241] . ACTH acutely and transiently reduced insulin-induced glucose uptake as well as reduced visfatin and adiponectin expression, whereas it stimulated the production of MCP-1 (monocyte chemoattractant protein-1) and IL-6 in white adipocytes, all of which led to a transient insulin-resistant state.
Thermogenesis and energy expenditure
ACTH directly regulated cultured mouse brown adipocytes, where it stimulated p38 MAPK (mitogen-activated protein kinase) signal transduction resulting in increased UCP1 expression [241] . If ACTH increased UCP1 in brown adipocytes in vivo, this would be expected to increase thermogenesis and energy expenditure.
Melanocortin peptides can regulate energy expenditure independently of leptin. Peripheral NDP-MSH produced a large and sustained increase in resting energy expenditure with similar responses in wild-type and in leptin-deficient ob/ob mice [232] . During periods of caloric restriction, weight loss is not sustained because compensatory mechanisms such as reduced RMR (resting metabolic rate) are brought into play. Hence reduced plasma α-MSH levels resulting from caloric restriction may contribute to the reduced RMR.
WHAT ELSE IS THERE TO UNDERSTAND ABOUT THE MELANOCORTIN SYSTEM AND ENERGY HOMOEOSTASIS?
Since 1997, progress in dissecting the melanocortin signalling pathways that contribute to the regulation of energy homoeostasis has been remarkable. A number of genes in the melanocortin signalling pathways have, and are, being pursued as potential drug anti-obesity targets [28, 36, [242] [243] [244] . There is, however, still a great deal that we have yet to learn about how the melanocortin system regulates appetite, body weight, insulin secretion and sensitivity, energy partitioning and food preference. This knowledge could lead to new ways of treating and/or preventing metabolic diseases. It is by understanding these mechanisms that we can hope for safe and well-tolerated treatments in the future.
Three recent developments in melanocortin signalling that I predict will be important to progress our understanding of how the melanocortin system regulates energy homoeostasis are (i) MRAPs, (ii) β-defensin ligands for MCRs, and (iii) autoantibodies against POMC-derived peptides and MC4R.
MRAPs
For many years, the melanocortin system was thought to comprise five MCR subtypes, POMC-derived peptide agonists and two naturally occurring antagonists, agouti protein and AgRP. MRAPs are new additions to the melanocortin system. The first MRAP, MC2R accessory protein, was discovered in a search for defective genes causing FGD (familial glucocorticoid deficiency) [245] . In humans, there are two alternatively spliced variants known as MRAPα and MRAPβ that share a common N-terminus and transmembrane domain, but diverge at the C-terminus. MRAPα and MRAPβ are absolutely required for MC2R to be functionally expressed in the plasma membrane and FGD type 2 is caused by defective mutations in the N-terminal coding region of MRAP [245] . MRAPα allows MC2R to function by first trafficking MC2R from the endoplasmic reticulum into the plasma membrane and then MRAPα is required for ACTH to bind and activate the receptor [246, 247] . All other MCR subtypes are functionally expressed in the plasma membrane without MRAPα. However, MRAPα and a second homologous MRAP gene, MRAP2, have been shown to interact with all five MCR subtypes in vitro and they reduce the responsiveness of MC1R, MC3R, MC4R and MC5R to melanocortin peptide coupling to adenylate cyclase [248] . Furthermore, MRAP2 has recently been shown to prevent MC5R from being expressed in the plasma membrane [249] . Hence, there is the potential for MRAPα, MRAPβ and MRAP2 to influence melanocortin signalling through any of the MCRs, especially since the MRAPs are expressed in numerous tissues, including the brain [245] , and some of these tissues do not express MC2R. It remains to be determined whether MRAPs play a role in regulating energy homoeostasis through influencing MC3R and/or MC4R functions in the brain. Regardless, a role for MRAPα in energy homoeostasis is likely because MRAPα was originally discovered as a protein that is up-regulated upon fat cell differentiation. MRAPα, previously known as fat-tissue-specific cell low-molecular-mass protein or Falp [250] , would be required for MC2R signalling in adipose tissue and may also influence MC5R functions in adipose tissue. If MRAPα does influence energy homoeostasis, then this does not generally manifest in FGD type 2 individuals. There is one report, however, of a potential association of obesity with FGD type 2. A novel homozygous frameshift mutation leading to a premature termination in exon 4 of MRAP was found in an obese FGD individual [251] . MRAP could play a role in this individual's obesity because the heterozygote parents and siblings of the person were either overweight or obese.
β-Defensin 3
The recent discovery of a new ligand for MC1R and MC4R came as a complete surprise. A powerful genetic study found that a mutation in the β-defensin 3 gene is responsible for the black coat colour in dogs and this is epistatic to MC1R and agouti genes [252] . Interestingly, a transgenic mouse overexpressing the variant β-defensin 3 gene developed a darker coat colour and had reduced body weight compared with wild-type littermates. Subsequently, β-defensin 3 was found to bind to both MC1R and MC4R. Just how β-defensin 3, an innate antimicrobial protein, signals through MC4R remains to be determined. Nevertheless, β-defensin 3 could be influencing energy homoeostasis through the melanocortin system.
MC4R auto-antibodies
The presence of MC4R auto-antibodies in obese human subjects was reported recently [253, 254] . When Peter et al. [253] introduced purified MC4R auto-antibodies from two obese individuals into rats by ICV injection, they observed a significant increase in food intake over 48 h. This suggested that these MC4R auto-antibodies could actually be causing obesity. If further studies identify MC4R auto-antibodies associated with obesity, then it will be important to determine how these auto-antibodies arise. Interestingly, autoimmunity and the melanocortin system have previously been associated with eating disorders. Autoantibodies against α-MSH and ACTH were detected in anorexia and bulimia nervosa patients [255, 256] .
PAST, PRESENT AND FUTURE
There are likely to more surprises when additional molecules contributing to the melanocortin system are exposed in the future. Some 12 years ago, we predicted functions for the POMC-derived peptides in energy homoeostasis, and many of these predictions have proved to be correct. The melanocortin system as it is now known is far more complex than most of us could have imagined, and similarly the importance of this system for regulating energy homoeostasis in the general human population is much greater than we would have predicted. Of the known factors that can cause human obesity, or protect against it, the melanocortin system is by far the most significant. 
